FLAG 01
High
Apomorphine, the headline differentiator, has no approved ED use and a withdrawn-product safety record.
The molecule that justifies the premium and the “arousal-signal” positioning is the weakest and least proven ingredient in the dissolvable tablet. Apomorphine is FDA-approved in the US only for Parkinson’s. Its sole sublingual ED product, Uprima, was never approved: an FDA advisory committee in April 2000 voted unanimously to approve the 2mg dose and 9-to-3 on the 4mg dose, but the sponsor (TAP) withdrew the application in June 2000 over documented hypotension, syncope, and bradycardia, including a driver who lost consciousness and a patient who fractured his skull. Trial success ran 26–55%, below the 60–80% of standard PDE5 inhibitors, and 89–94% of men found the 2mg dose insufficient and escalated to higher doses, where the side effects worsened. The differentiation is built on a molecule whose only ED bid was pulled on safety.
Why it’s material
Any superiority or efficacy claim that leans on apomorphine rests on marketing, not approved evidence, and a safety signal or enforcement action would strike the core product, not a side line.
Evidence
FDA approvals for apomorphine are Parkinson’s-only (Apokyn, Onapgo). Uprima NDA withdrawn June 2000 after the April 2000 advisory committee (thepharmaletter; Public Citizen rejection letter; PMC). Efficacy 26–55% vs PDE5 60–80% (ScienceDirect; Springer).
Verify
The per-tablet apomorphine dose and the medical-director rationale; whether the dose is high enough to carry Uprima’s safety profile or too low to deliver the claimed effect; adverse-event reports citing dizziness, fainting, or low blood pressure; counsel’s read on marketing an unapproved-for-ED dopamine agonist.
FLAG 02
High
The arousal benefit is unsupported at the actual dose, which Rugiet does not disclose.
The clinical figure cited for apomorphine, roughly a doubling of erectile response versus placebo, comes from Uprima-era trials at 2–3mg, the same doses that drove the dropouts and syncope. Rugiet states each ingredient is physician-customized and publishes no apomorphine quantity. Either the dose carries the withdrawn product’s safety profile, or it is too low to deliver the cited effect and the central differentiator is decorative. This is the checkable gap between the headline and what the patient receives.
Why it’s material
The entire premium rationale turns on a dose Rugiet will not state.
Evidence
Rugiet RD-37 pages describe physician-customized doses with no milligram amounts; the doubling figure traces to 2–3mg sublingual apomorphine trials.
Verify
Request the apomorphine milligrams per tablet across standard strengths; map against the published dose-response and safety curve; determine whether the cited efficacy is achievable at the dispensed dose.
FLAG 03
High
“Clinically proven, 3x stronger than generics” has no head-to-head study and creates direct FTC exposure.
The product page leads with “3x Stronger Than Generics,” “clinically proven,” “85% of men feel more confident,” and “80% of men prefer Rugiet,” with the 15-minute onset footnoted to a survey of 114 patients in May 2025. No controlled trial compares the full dissolvable tablet to generic sildenafil or tadalafil. FTC health-products guidance requires randomized controlled evidence for “clinically proven” and treats consumer surveys as insufficient substantiation for efficacy claims. The 400,000-patient figure appears only in a March 2026 release, never on the product page, and none of these numbers belong in a model as independent fact.
Why it’s material
This is among the fastest paths to an FTC investigative demand, and an action would strike the product’s central selling line and pricing rationale. Enforcement has already reached this exact pattern: the FDA’s September 2025 warning letter to BlueChew (Dermacare LLC) targeted a compounded-ED seller’s “same active ingredients as approved Viagra/Cialis” claim.
Evidence
rugiet.com/erectile-dysfunction/ready (verbatim claims, 114-patient survey footnote); FTC Health Products Compliance Guidance; FDA BlueChew letter 716698, 9 Sept 2025.
Verify
Demand the substantiation file behind “clinically proven” and “3x stronger”; identify any registered trial; have counsel price the FTC/FDA exposure and the cost of pulling the claim.
FLAG 04
High
The compounded core product sits in active FDA enforcement that just narrowed.
Rugiet Ready and the new compounded weight-loss line are not FDA-approved, disclosed on Rugiet’s own safety page. On 20 February 2026 (public 3 March) the FDA sent warning letters to exactly 30 telehealth companies marketing compounded GLP-1 drugs, citing claims implying sameness with approved products and branding that obscured the actual compounder, the same patterns in Rugiet’s materials. That was a second wave; a broader 2025 campaign preceded it. The statutory basis is contested: 503A compounding is tied to individual patient-specific prescriptions, not one branded formulation sold nationally. The SAFE Drugs Act of 2025 (H.R. 6509, introduced 9 December 2025 by Reps. Yakym and Carson; Senate companion S. 3794, referred to HELP 5 February 2026) would cap “essentially a copy” compounding at 20 copies per month and require FDA reporting for drugs shipped on more than 20 out-of-state prescriptions. Both remain in committee, not enacted. Separately, stacking two PDE5 inhibitors carries additive blood-pressure lowering, and apomorphine adds syncope risk, an adverse-event tail that scales with the asserted 400,000-patient base.
Why it’s material
A live binary regulatory risk on the core product, plus a clinical-safety tail, both landing on the flagship rather than a peripheral line.
Evidence
FDA 30-letter announcement, 20 Feb 2026 (fda.gov); H.R. 6509 / S. 3794 (congress.gov; Carson press release); additive PDE5 hypotension (AHA Circulation); Rugiet safety page.
Verify
Whether Rugiet compounds in-house or via a 503A/503B partner and whether each prescription is genuinely patient-specific; revenue exposure if a per-patient monthly cap passes; whether marketing implies the company is the compounder or implies approval.
FLAG 05
High
Company-asserted revenue above $100M does not reconcile with a 51–62-person headcount.
The >$100M and 400,000-patient figures trace to a single March 2026 press release, unaudited. Independent trackers read far lower: Growjo near $7.1M, a $10–25M low-end band, with the widest spread reaching $100–250M on one tracker and $1–5M on another. At 51 employees (December 2025) rising to 62 (April 2026), >$100M implies roughly $1.6–2.0M revenue per employee, a category outlier; Hims books about $2.35B at vastly greater scale. The $10–25M range implies a plausible $140K–500K per employee. A 2.7M-visit, 67%-bounce traffic profile supports a $15–40M defensible band as our triangulation, not an independent figure.
Why it’s material
The four-to-ten-times gap is the difference between a scaled business and a small one, and it sets the valuation directly. The company cannot be priced on an unverifiable top line.
Evidence
March 2026 TRT-expansion release (Yahoo Finance); Growjo, LeadIQ trackers; headcount ~51–62 (Growjo).
Verify
Audited or bank-verified 2025 revenue, processor settlement data, and a cohort/MRR breakdown; separate gross billings from net revenue and one-time consult fees from recurring subscription revenue; reconcile against headcount and tracked traffic.
FLAG 06
High
A $31M senior loan ahead of any new equity is the runway tell.
Late in 2025, Rugiet reportedly secured a $31M private-credit loan from Deep Ocean Partners. The transaction is single-source and unconfirmed beyond one LinkedIn post citing a paywalled Debtwire exclusive; Deep Ocean Partners is a real 2022-founded NYC private-credit firm, which lends plausibility but does not confirm the deal. A sub-scale DTC brand taking debt rather than raising equity signals no up-round and a liquidity need. We read the debt as ranking ahead of equity, so a follow-on from an existing backer would sit junior to it — that seniority is our judgment, not a reported term. If confirmed, this is the single most material new fact since the prior read, and the loan terms (rate, maturity, covenants, warrants) are not public.
Why it’s material
Structure and seniority change the risk on any new check, and the choice of debt over equity is itself a signal about the equity market’s appetite for the company.
Evidence
Debtwire exclusive (via Amelia Weitzman, LinkedIn); Deep Ocean Partners founding per its own materials. The seniority read is our judgment, not a reported term.
Verify
Full loan terms, covenants, and any warrant coverage; how the proceeds are deployed against the four-vertical expansion; runway under tracker-range revenue rather than the asserted figure.
FLAG 07
Medium
Auto-renewal complaints map onto reopening FTC negative-option rules.
The subscription is the revenue engine and a live liability. The BBB profile shows an A+ company rating and 33 complaints over three years dominated by unwanted renewals, cancellation difficulty, and unauthorized charges; a customer-review average near 1.86 stars was captured earlier on a small sample and should be presented as such, with Trustpilot more favorable near 4.2. These harms match the FTC’s negative-option targets exactly. The Eighth Circuit vacated the FTC click-to-cancel rule on 8 July 2025 on procedural grounds, and the FTC reopened the rulemaking with a March 2026 advance notice, so the direction is tightening. Forced cancellation-flow changes would raise churn, and cancellation friction inflates reported subscriber and lifetime-value figures.
Why it’s material
Both a churn liability and a regulatory exposure, and it casts doubt on the retention numbers any model would use.
Evidence
BBB Austin profile (A+, 33 three-year complaints); FTC click-to-cancel vacated July 2025, ANPRM March 2026 (FTC; coverage).
Verify
The cancellation flow and renewal-disclosure UX; chargeback and refund rates; involuntary churn; counsel’s gap analysis against the reopened FTC requirements.
FLAG 08
Medium
Acquisition economics rest on bought traffic against one revenue line.
Rugiet owns no organic channel and buys customers (paid social ~21% of desktop visits, paid keywords ~19%) in the same auction as Hims, whose acquisition cost runs near $929 but is earned back across multiple conditions and years. A single-vertical brand pays the giants’ price and recovers one revenue line, capping contribution margin and tying growth to continuous ad spend. The March 2026 multi-condition expansion is the intended fix, unproven and adding regulatory surface.
Why it’s material
The unit economics do not close at scale without an owned channel or cross-sell, and the fix spreads a 51–62-person team across four verticals at once.
Evidence
SimilarWeb (directional) channel mix; Hims CAC ~$929 (verified). That Rugiet “pays near $929” is our inference; its actual CAC is undisclosed.
Verify
Blended and paid CAC, payback period, contribution margin per cohort; early cross-sell and retention from the new lines; whether any non-paid channel is emerging.